🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Denmark / NCT04522921
Active, not recruiting Not applicable

Childhood Obesity - Prevention of Diabetes Through Changed Eating Patterns

NCT04522921 · tracked via the Priya Life Science Denmark tracker
Phase
Not applicable
Started
2020-10-01
Last updated
2026-04-29

Condition(s) studied

Childhood ObesityOverweight and ObesityAdolescent ObesityAdolescent OverweightDiabetes

Investigational drug(s) / intervention(s)

Diet with a higher amount of protein (25E% per day)Increased follow-up contact after the 10-week interventionDiet with a lower amount of protein (15E% per day)

Diet with a higher amount of protein (25E% per day): In a caloric restricted and increased physical activity setting, the participants will be served a higher protein (25E%/day) diet.

Increased follow-up contact after the 10-week intervention: Both the control-group and the intervention-group were offered an increased follow-up contact after camp.

Diet with a lower amount of protein (15E% per day): In a caloric restricted and increased physical activity setting, the participants will be served a low-moderate protein (15E%/day) diet.

Study summary

The main purpose of the present study is to perform a 10 weeks dietary intervention study with a follow-up for 52 weeks in children from 7-14 years of age with overweight or obesity. In a caloric restricted and increased physical activity setting the control group will consume a low-moderate protein (15E%/day) diet whereas the intervention group will consume a higher protein (25E%/day) diet. Secondary, the investigators want to investigate the effect of frequent follow-up after the intervention, and the overall effect of the lifestyle camp.

Compared to the low-moderate protein diet, the investigators hypothesis that a diet with higher consumption of protein-containing foods will more effectively induce weight loss (a reduction in BMI-SDS) or weight maintenance in children with overweight or obesity, and improve quality of life, and risk factors for type 2 diabetes.

Eligibility

Sex
ALL
Min age
7 Years
Max age
14 Years
Healthy volunteers
Accepted
Inclusion Criteria: * The child attends a multi-component-overnight camp in Hobro or Fjordmark between October 2020 and March 2022. * The child is between 7 and 14 years of age (inclusive) while attending camp. * At least one parent/guardian submit written and oral consent to participate with his/her child. * Parent/legal guardian has submitted oral and written consent to participation of their child. In case of shared custody both parents must submit written and oral consent before their child can participate in the trial. Exclusion Criteria: * The child has a disease, diagnose or eating disorder that require treatment. * The child or parent/guardian participate in another clinical trial or plan to do so in the near future. * The parent/guardian do not understand the written informed consent. * The child or parent/guardian are unwilling to or unable to comply with the study protocol and instruction given by the study staff.

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Weight Loss Camp Hobro Hobro Denmark
Weight Loss Camp Fjordmark Kruså Denmark

More University of Aarhus trials in Denmark

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04522921 on ClinicalTrials.gov ↗ ← All trials in Denmark